Company Achievements and Recognition - In 2022, Chengdu Okay Pharmaceutical Co., Ltd. was awarded the title of "Little Giant" enterprise by the Ministry of Industry and Information Technology in July[5]. - The company successfully went public on the Beijing Stock Exchange on December 9, 2022[5]. - The National Medical Products Administration approved the listing application for the chemical raw material drug (Diosmin) on October 27, 2022[5]. - The company is recognized as a national high-tech enterprise and has been included in the list of national "specialized, refined, and innovative" small giant enterprises[49]. Financial Performance - The company's operating revenue for 2022 was RMB 269,435,957.14, a decrease of 10.44% compared to RMB 300,858,164.15 in 2021[30]. - The net profit attributable to shareholders for 2022 was RMB 33,662,612.94, down 19.69% from RMB 41,916,154.19 in 2021[30]. - The total assets at the end of 2022 reached RMB 440,473,318.89, an increase of 104.27% from RMB 215,629,712.12 in 2021[32]. - The total liabilities decreased by 30.14% to RMB 50,225,567.49 in 2022 from RMB 71,894,404.96 in 2021[32]. - The net assets attributable to shareholders increased by 171.50% to RMB 390,247,751.40 in 2022 from RMB 143,735,307.16 in 2021[32]. - The basic earnings per share for 2022 was 0.57, a decrease of 21.92% from 0.73 in 2021[30]. - The company's gross profit margin for 2022 was 22.51%, down from 24.30% in 2021[30]. - The company achieved total revenue of 269.44 million yuan, a decrease of 31.42 million yuan or 10.44% compared to the same period last year[52]. - Net profit was 33.66 million yuan, a decline of 8.10 million yuan or 19.40% year-on-year, primarily due to a 19.69% drop in revenue from the company's main product series[52]. Risks and Challenges - The company faces risks related to the expiration of product quality certifications, which could adversely affect its operations if not renewed[11]. - International trade environment changes could impact the company's overseas sales, particularly in developed markets like Europe, the US, and Japan[11]. - The company is exposed to risks from fluctuations in raw material supply and prices, which could significantly affect its financial performance[12]. - The company has identified potential risks related to the inability to timely digest new production capacity, which could impact economic benefits from investment projects[13]. - The company’s core product, Quercetin, may face market growth challenges if promotional efforts do not meet expectations[13]. - The company is heavily reliant on overseas markets for product sales, which poses risks if international policy or economic conditions change[118]. - The company is at risk of losing core technical personnel, which could impact production and operational efficiency[117]. Research and Development - The company has established a technical innovation system combining product R&D and technology application, focusing on the development of natural vitamin P compounds[46]. - The company has received multiple certifications including EuGMP, FSSC22000, HACCP, ISO22000, ISO9001, HALAL, and KOSHER, enhancing its market credibility[47]. - The company aims to become a global leader in the application of natural vitamin P compounds, with a focus on sustainable development and safety[45]. - The company has formed partnerships with institutions like the Chinese Academy of Sciences and universities for collaborative R&D[46]. - The company continues to focus on the development of new products and technologies, aiming to expand into domestic markets for raw pharmaceuticals, functional food ingredients, food additives, feed additives, and cosmetic raw materials[54]. - The company has a total of 27 patents, including 4 invention patents, showcasing its strong technical foundation in the plant extraction field[62]. - The company has initiated research on the production process of the EMIQ technology, which is currently in the small-scale testing phase, with the goal of developing new products and entering new markets[99]. Market and Industry Trends - In 2022, China's plant extract exports reached 3.53 billion USD, a year-on-year increase of 16.5%[57]. - The global market for plant extracts is expected to reach 59.4 billion USD by 2025, driven by increasing consumer demand for natural and healthy products[57]. - The competitive landscape of the plant extract industry in China is characterized by a low concentration of firms, with 88% of export companies earning less than 1 million USD[60]. - The company is positioned to benefit from supportive policies aimed at the health management and traditional medicine sectors, which will enhance the market for plant extracts[59]. Corporate Governance and Compliance - The company has established a new corporate governance system during the reporting period[190]. - The company has implemented key internal controls related to revenue recognition to mitigate risks associated with improper revenue reporting[102]. - The company has conducted thorough audits of its inventory measurement processes to ensure accuracy and compliance with accounting standards[104]. - The company has committed to strict compliance with profit distribution policies and measures to address any violations of these commitments[125]. - The company has established a mechanism to ensure equal rights and protection for all shareholders[192]. Future Plans and Investments - The company plans to expand its domestic market by developing raw materials for pharmaceuticals, functional food ingredients, and food additives[113]. - The company has established a subsidiary in the United States to develop new products and facilitate cross-border e-commerce sales[113]. - The company plans to publicly issue shares to unspecified qualified investors and list on the Beijing Stock Exchange[199]. - The company plans to use the raised funds for technical transformation projects, working capital supplementation, and repayment of bank loans[147]. - The technical transformation project in Chengdu is expected to enhance production capacity[147]. Employee and Management - The company has a total of 53,484,865 shares held by directors, supervisors, and senior management, representing 70.70% of the total shares[160]. - The total number of employees increased from 206 to 208, with a net addition of 2 employees during the reporting period[167][168]. - The employee compensation policy includes regular adjustments based on performance evaluations and annual assessments[169]. - The company emphasizes training and development for employees to enhance their skills and performance[169]. Environmental and Social Responsibility - The company emphasizes its commitment to social responsibility, including timely tax payments and environmental protection, while providing quality services to customers[107]. - The company has implemented a strict management system for hazardous waste and chemicals, ensuring compliance with relevant laws and regulations[188]. - The company has maintained a "zero accident" safety and environmental protection policy, with increased investment in safety and environmental measures[190].
欧康医药(833230) - 2022 Q4 - 年度财报